vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here.

The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist and T1D advocate Alisa Weilerstein. Together, they will join company management to discuss: * Ongoing challenges for individuals living with T1D and the current treatment landscape * Hypoglycemia risk and the experience of living with T1D * Cadisegliatin, vTv’s novel, potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin in T1D * An overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D with topline data expected in mid 2027 A live question-and-answer session will follow the formal presentations. Following the event, a replay will be available in the Investor Relations section of the Company's website.